ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of Lytenava (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, has reported financial results for the third quarter of fiscal year 2026, ended June 30, 2026, and provided a business update. For the third fiscal quarter, the company reported a net loss attributable to common stockholders of $20.3 million compared with a net loss of $20.2 million attributable to common stockholders for the prior-year period.
Adjusted net loss saw an improvement to $10.9 million in Q3 compared with $15.8 million for the prior-year period, while revenue fell to $9,000 in Q3 2026 compared with $1.5 million in the prior-year period, resulting in a negative gross profit, the company reported.
The company also reported cash and cash equivalents of $11.2 million as of June 30, 2026, and earlier this month closed an additional public offering raising approximately $55 million in net proceeds to prepare for the U.S. commercial launch of Lytenava, which was approved by the Food and Drug Administration (FDA) last month to treat wet AMD.
In making the financial announcement, the company also shared that it continues to advance preparations for the U.S. commercial launch of Lytenava, the only FDA-approved ophthalmic bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). With the launch planned before the end of calendar 2026, the company said it is expanding payer engagement, scaling commercial supply, and building a focused commercial organization informed by feedback from retina physicians, practices, and other key stakeholders.
Management noted in a conference call that, based on current projections, Lytenava has the potential to generate over $500 million in annual U.S. sales by 2030.
“FDA approval of Lytenava marks a defining moment for Outlook Therapeutics and creates a significant opportunity for the company in the United States,” said Bob Jahr, CEO of Outlook Therapeutics. “Our priorities are clear: build an exceptional commercial team with deep retina and launch experience, prepare for our planned U.S. launch by the end of calendar 2026, and execute a strategy that reflects today’s competitive and evolving wet AMD treatment landscape. We believe Lytenava is well positioned to become an important treatment option for retina physicians and their patients.”
He added, “Our launch strategy reflects a deep understanding of the retina market and the needs of patients, physicians, practices and payers. We are taking a targeted approach to customer engagement, pricing, and reimbursement, while building the commercial and supply capabilities needed to support the introduction of Lytenava in the United States. We believe this foundation will position us to drive broad access and successful adoption following launch.”
Outlook Therapeutics said it continues to expand the commercialization of Lytenava in Germany, Austria and the United Kingdom, and the company is also preparing for a planned launch in the Netherlands later in 2026 following its Netherlands submission. In Switzerland, the company’s partner, Mediconsult, is leading regulatory and commercial activities in support of an anticipated launch in 2027, the announcement noted.
